Can We Cure Type 1 Diabetes?

There’s a cliché in the type 1 diabetes community that a cure has been “five years away” for as long as anyone can remember. For decades, patients have been told that researchers were on the verge of a miraculous breakthrough. It hasn’t come true yet.
Is there a cure for type 1 diabetes? The short answer is no. And even if an experimental cure were discovered tomorrow, it would almost certainly take much longer than five years before it became available to most people with type 1.
But there are still reasons to be optimistic. While it seems unlikely that type 1 diabetes will be solved in a single stroke of genius, in the past several decades researchers have made significant progress toward therapies that could one day free many patients of the need to use insulin.
What Does a ‘Cure’ Mean for Type 1 Diabetes?
Type 1 diabetes is an autoimmune disease in which the body’s immune response mistakenly attacks the islet cells in the pancreas that create insulin, a hormone that is absolutely critical to human life.
For most, a cure for type 1 diabetes would mean a therapy that would restore the body’s ability to produce its own insulin. Someone who had been cured would achieve and maintain normal blood sugar levels without the need for insulin injections or ongoing diabetes management.
Camillo Ricordi, MD, director emeritus of the Diabetes Research Institute in Miami, goes a little bit further. He believes that a cure has to restore normal blood sugar levels “without antirejection drugs or any toxic interventions that may introduce other problems. You cannot replace diabetes with another disease.”
The past two decades have yielded tremendous progress on therapies that could possibly restore insulin independence, even if they do not reverse the autoimmunity that caused it in the first place. These therapies rely on pancreas and stem cell transplants. But because they still require immunosuppressive drug regimens to protect the transplanted cells, they are therefore arguably not true cures.
Pancreas Transplants
Some people who receive a new pancreas will no longer need to use insulin or check their blood sugar. Their type 1 diabetes has essentially gone away.
- The recipient will need to take antirejection drugs for the rest of their life.
- Only a little more than half of recipients achieve true insulin independence; others will need to continue using insulin.
- Transplantation surgery is intense, expensive, and potentially risky.
- Donor pancreases are very rare.
The bottom line is that pancreas transplants can be a more burdensome treatment option than simply continuing to use insulin.
As a result, pancreas transplants are only rarely performed. Most of the time they are limited to people who are already receiving a kidney transplant for end-stage diabetic kidney disease, or for people with extreme management challenges, such as dangerous hypoglycemia unawareness.
Islet Cell Transplants
In an islet cell transplant, only the insulin-producing islet cells are transplanted, rather than the entire pancreas. This procedure is less invasive than a pancreas transplant: Donated islet cells are processed and purified, then transported through a thin tube to the recipient’s liver.
The transplant can have excellent results. Some lucky transplant recipients have enjoyed healthy blood sugar without the use of insulin for a decade or more.
Lab-Grown Islet Cell Transplants
This treatment, which could be manufactured on a vast scale, is perhaps the experimental therapy closest to being a practical cure for type 1 diabetes. But it still must pass through years of vigorous stage 3 testing, which will evaluate the treatment’s safety and efficacy in a larger number of volunteers. Even if it succeeds and is approved, we don’t yet know if zimislecel will become available for almost anyone with type 1 diabetes, or if it will be limited to people with a more distinct need.
The Final Step: Avoiding Immunosuppression
“The ultimate goal is to do these transplants without immunosuppression,” says Ricordi.
- Gene-editing techniques that can hide transplanted islet cells from the immune system
- Physical barriers that encapsulate islet cells, allowing glucose and insulin to flow freely while blocking immune cells
- Immunosuppressive microgels that can be mixed with islet cells, preventing the need for chronic antirejection drug use
- Nanocarriers that can deliver small precise amounts of immunosuppressive drugs exactly where they’re needed
Islet Cell Regeneration
Transplantation isn’t necessarily the only path toward a cure.
Other researchers are exploring therapies that aim to regenerate the body’s natural capacity to produce insulin. The pancreas of an adult with type 1 diabetes may still contain progenitor cells that can be instructed to turn into insulin-producing beta cells. Alternatively, beta cells can possibly duplicate themselves, which could allow a noninvasive therapy to cause even a tiny amount of beta cells to proliferate.
Timeline and Cost
Ricordi has worked at the forefront of diabetes research for decades. He believes that we could be only years away from experimental proof of a real type 1 diabetes cure: one that can restore insulin production and hide the transplanted or rejuvenated islet cells from the immune system.
But even in that optimistic scenario, there is no telling how many years it would take to get a cure out of the lab and into the bodies of people with diabetes. Ricordi cautions that even after a true cure is confirmed under experimental conditions, “it will take five years to follow up on the initial group.” Then it will take even longer to scale up and make the therapy widely available.
Even after FDA approval, such a cure could be limited to only a tiny subset of people with the condition. It may be extraordinarily expensive, too. “Advanced cell therapies can cost hundreds of thousands of dollars,” Ricordi says.
While the progress we’ve made toward a cure is exciting, it wouldn’t be wise to expect your own type 1 diabetes to be cured at any point in the foreseeable future. “We don’t want to create false hope,” Ricordi says.
Automated Insulin Delivery Systems
Although an insulin pump will never be a true cure for diabetes, some people hope that this technology can become so advanced that it will act almost as if it were a cure, removing almost all of the worries and burdens of people with type 1 diabetes. A theoretically perfect insulin pump system — one that could keep your blood sugar in range no matter what food or exercise decisions you made — would alleviate a massive amount of the cognitive and emotional burden of living with the disease.
Automated insulin delivery (AID) systems combine a continuous glucose monitor (CGM) and an insulin pump so that they communicate with each other. A computer-controlled algorithm, which might reside in a smartphone or on the pump itself, decides exactly how much insulin you need, adjusting the delivery rate constantly around the clock.
But in the future, we may have AID systems that work so quickly that patients will no longer need to count their carbs. It’s possible to imagine a pump system so good that it lets you forget about your diabetes, at least for a few days at a time.
The Takeaway
- Today, there is no cure for type 1 diabetes.
- Pancreas and islet cell transplants can, in some cases, remove the need for insulin therapy. But these therapies are not widely available and still require the lifelong use of immunosuppressive drugs.
- Automated insulin delivery systems and continuous glucose monitoring greatly aid in diabetes management and improve quality of life, but they are not a cure.
- Researchers have made impressive advances toward a type 1 diabetes cure, and the condition is easier to manage than ever. But even in the most optimistic scenario, a new diabetes cure would take many years to become available.
Resources We Trust
- Cleveland Clinic: How to Care for Your Child Living With Type 1 Diabetes
- Diabetes Research Institute: Is There a Cure for Type 1 Diabetes?
- Breakthrough T1D: Curing T1D
- Diabetes UK: Research on a Cure for Type 1 Diabetes
- Association of Diabetes Care & Education Specialists: Automated Insulin Delivery, A Quick Overview
- Ugo B et al. Treating Type 1 Diabetes by Pancreas Transplant Alone: A Cohort Study on Actual Long-term (10 Years) Efficacy and Safety. Transplantation. January 2022.
- Lablanche S et al. Ten-Year Outcomes of Islet Transplantation in Patients With Type 1 Diabetes: Data From the Swiss-French GRAGIL Network. American Journal of Transplantation. November 2021.
- Islet Transplant for Type 1 Diabetes. University of California San Francisco.
- Hogrebe NJ et al. Developments in Stem Cell-Derived Islet Replacement Therapy for Treating Type 1 Diabetes. Cell Stem Cell. May 4, 2023.
- Reichman TW et al. Stem Cell–Derived, Fully Differentiated Islets for Type 1 Diabetes. The New England Journal of Medicine. June 20, 2025.
- Kabakchieva P et al. Islet Transplantation-Immunological Challenges and Current Perspectives. World Journal of Transplantation. June 18, 2023.
- Tondin AR et al. Islet Cell Replacement and Regeneration for Type 1 Diabetes: Current Developments and Future Prospects. Biodrugs. February 7, 2025.
- First-Of-Its-Kind Cell Transplant Brings a Cure For Diabetes Closer. Science Alert. August 18, 2025.
- Lei J et al. FasL Microgels Induce Immune Acceptance of Islet Allografts in Nonhuman Primates. Science Advances. May 13, 2022.
- Pang H et al. Nano-Based Therapy for Type 1 Diabetes: From Immuno-Intervention to Insulin Delivery. Acta Biomaterialia. July 1, 2025.
- VX-264: A Diabetes Breakthrough That Didn’t Work as Planned. Beyond Type 1. March 31, 2025.
- Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine. Eledon Pharmaceuticals. October 29, 2024.
- Polonsky WH et al. 109-LB: Quality of Life Benefits for Insulin-Using Adults with Type 2 Diabetes after Six Months of Pump Therapy—A Quasi-experimental Approach. Diabetes. June 20, 2023.

Kacy Church, MD
Medical Reviewer
Dr. Church always knew that she wanted to pursue endocrinology because the specialty allows for healthy change through patient empowerment. She completed her fellowship in endocrinology, diabetes, and metabolism in 2017 at Stanford University in California.
She loves running, dancing, and watching her sons play sports.

Ross Wollen
Author
Ross Wollen joined Everyday Health in 2021 and now works as a senior editor, often focusing on diabetes, obesity, heart health, and metabolic health. He previously spent over a decade as a chef and craft butcher in the San Francisco Bay Area. After he was diagnosed with type 1 diabetes at age 36, he quickly became an active member of the online diabetes community, eventually becoming the lead writer and editor of two diabetes websites, A Sweet Life and Diabetes Daily. Wollen now lives with his wife and children in Maine's Midcoast region.